Thursday, May 28, 2020 7:44:14 AM
this write up points out so many things.
As the writter points out on the rev.possibilties the ASD looks to be
the leader.Plus the writter points out the numbers are consevative.
As we know yesterdays phase 2 ASD trial results met EVERY idicator.Now on to phase 3.
Phase 3 with FX is done ,and will be next news.My main focuss is,and will remain to be...BUY MORE DOWN HERE.??
The benefits in the behavioral components of FXS have led to the development of Zygel for other syndromes with behavioral manifestations. These include ASD and 22q. ASD affects nearly 1 million patients, and can include symptoms such as anxiety, repetitive patterns of behavior, impairment in social communication, and social impairment. There are limited products approved for ASD as of present time. The BRIGHT study is a 14 week trial evaluating Zygel in ASD patients. The trial is a single arm trial that will evaluate the effect of Zygel on several aspects of behavior and anxiety. Results of this trial are expected in the second quarter. Finally, we have 22q, which affects around 81,000 patients in the United States. This disorder results in neuropsychiatric illnesses including anxiety. Presently, there are no approved drugs for the treatment of 22q, which paves the way for Zygel to be a first to market product. The INSPIRE trial is evaluating the use of Zygel for patients with 22q11.2 deletion syndrome, and will look at the neuropsychiatric effect at 14 weeks, similar to the BRIGHT trial. Results of this trial are expected in the third quarter of 2020. So lets look at the market opportunity here. The current WAC price of Epidiolex is around $32,500 annually. We will use a similar price point for our estimates. Using the market opportunities as estimated by Zynerba, we arrive at these conservative annual revenue for Zygel:
FXS (10% market penetration): $210 million annually
ASD (2% market penetration): $585 million annually
22q (10% market penetration): $240 million annually
These estimates do not include any potential revenue from a DEE indication either. As you can see, these potential revenues far exceed the current valuation (market cap of $100 million). So where is the disconnect? Well when Zynerba released their most recent DEE, the stock sold off sharply on what is perceived to be safety concerns. Most people will point to the infection-related adverse events. First, in clinical trials, all adverse events are reported, whether they are related to trial drug or not (runny nose, ingrown toenail, scrapes, etc.). So the absolute rate of adverse events is misleading. Furthermore, what people need to understand is that these patients are medically fragile. Many of these patients have co-morbid conditions such as cerebral palsy, chronic respiratory infections, tracheostomies (breathing tubes), and feeding tubes. Many of these conditions predispose patients to frequent health care visits (risk factor for infection) and infections (breathing tubes). To be honest, it is not surprising these patients had infections, but it is more likely related to their other conditions and not related to treatment with Zygel. All of this concern overshadowed the fact that Zygel resulted in a 44% median reduction in seizures by month 2. Furthermore, only one patient discontinued therapy with Zygel (due to application site reaction).
Recent ZYNE News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 12:22:51 AM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 10/19/2023 08:48:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/12/2023 04:15:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:12:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:02:08 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 10/11/2023 01:27:41 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/11/2023 01:27:00 PM
- Form SC 14D9/A - Solicitation, recommendation statements: [Amend] • Edgar (US Regulatory) • 10/11/2023 12:56:22 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 10/11/2023 12:31:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 12:17:36 PM
- HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE • PR Newswire (US) • 10/11/2023 12:00:00 PM
- Form SC 14D9/A - Solicitation, recommendation statements: [Amend] • Edgar (US Regulatory) • 10/04/2023 09:29:21 PM
- Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions • GlobeNewswire Inc. • 10/04/2023 08:05:00 PM
- Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 • GlobeNewswire Inc. • 09/29/2023 01:00:00 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM